# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $5 to...
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.2...
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.9...
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.
Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited fina...